De novo mutation of CYBB gene in a boy presenting as intra-abdominal infection of Burkholderia contaminans: a case report

Qianqian Zhao, Jing Yin, Jijun Ma, Xiaoxue Liu, Jiawen Wu and Chongwei Li*

Abstract

Background: Chronic granulomatous disease (CGD) is an inborn error of immunity. It is characterized by recurrent bacterial or fungal infections, including infections by Burkholderia species. This is due to respiratory burst dysfunction of phagocytes. Currently, there is no report on Burkholderia contaminans (B. Contaminans) infection in children with CGD.

Case presentation: We present a previously healthy, 17-month-old Chinese boy infected with B. Contaminans in the intra-abdominal regions. Immunological screening, including assessment of cellular immunity and humoral immunity did not yield conclusive results. The level of nicotinamide adenine dinucleotide phosphate (NADPH) activity was decreased and whole-exome sequencing identified a de novo mutation in the CYBB gene.

Conclusions: For specific pathogens such as B. Contaminans, immune assessment should be carried out even if there is no positive medical history or specificity in basic immunity screening.

Keywords: Chronic granulomatous disease (CGD), CYBB, De novo, Mutation, Abdominal infection, Burkholderia contaminans

Background

Chronic granulomatous disease (CGD) is a rare inborn error of immunity with an incidence of 1/250000 to 1/200000 and high mortality rate [1]. Defects in genes encoding various components of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex are associated with a dysfunctional respiratory burst, which decreases the ability of phagocytes to kill catalase-positive bacteria and fungi [2]. Mutations in CYBB, CYBA, NCF1, NCF2, NCF4, and CYBC1 genes have been associated with CGD [3]. About 70% of CGD cases are caused by defects in the CYBB gene, which is located on the short arm of the X chromosome (Xp21.1-p11.4). The gene encodes the gp91phox subunit that causes X-linked CGD (XLR-CGD). Defects in genes encoding the other NADPH oxidase subunits, including p22phox, p47phox, p67phox, and p40phox, lead to autosomal recessive CGD (AR-CGD). CYBB gene mutations include deletions, insertions, nonsense mutations, missense mutations, or splicing errors. Most CGD cases associated with CYBB gene mutations are hereditary and about 10 to 15% of cases are due to de novo mutations [4].

Patients with CGD mainly present with recurrent bacterial or fungal infections, granuloma formation, BCG-osis, inflammatory manifestations, and autoimmune phenomena (cutaneous lupus erythematosus, idiopathic thrombocytopenia or juvenile idiopathic arthritis). Burkholderia cepacia (B.cepacia) is the most widely known as a susceptible pathogen of CGD. However, B. Contaminans infection in children with CGD has not been reported.
Here, we describe a case of a 17-month-old boy infected with B. Contaminans in the intra-abdominal region, who was later diagnosed with XLR-CGD, characterized by de novo nonsense mutation in exon 6 of the CYBB gene (c. 603C > A).

**Case presentation**

A 17-month-old boy was hospitalized on April 27, 2021, due to swelling in the right scrotum for seven days. He was previously healthy and has a healthy, 11-year-old brother. There was no family history of immunodeficiency or recurrent infections. Routine immunization with Bacillus Calmette-Guerin (BCG) was administered without any untoward consequences. Physical examination showed painless bilateral cervical lymphadenopathy (about 1.0 cm in diameter), a normal BCG scar, no cardiopulmonary abnormalities, a soft palpable abdomen without tenderness with a circumference of 54 cm, no skin rash, and an enlarged right scrotum. Routine blood tests showed moderate anemia (hemoglobin 82 g/L, MCV 63.2 fL, MCH 19.0 pg, MCHC 301 g/L), leukocytosis (23.56 × 10⁹/L), neutrophils 57%, lymphocytes 33%, monocytes 10%, and thrombocytosis (523 × 10⁹/L). Other tests showed increased erythrocyte sedimentation rate (ESR 53 mm/h, normal value < 20 mm/h), C-reactive protein (CRP 16.36 mg/dL, normal value < 0.8 mg/dL), pro-calcitonin (PCT 1.72 ng/mL, normal value < 0.05 ng/mL), and D-Dimer (D-Dimer 13460 ng/mL, normal value < 550 ng/mL). Albumin, ferritin, lactate dehydrogenase (LDH), alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglycerides and fibrinogen were within the normal range, which did not meet HLH diagnostic criteria. Serum IgG and IgA levels were slightly increased to 1082 mg/dL (reference 453-916 mg/dL) and 115 mg/dL (reference 21-100 mg/dL) respectively, while IgM and IgE levels were normal. A flow cytometric analysis of lymphocyte subsets showed CD3⁺ cells of 45.55% (reference value 53.88-72.87%), CD3⁺ CD8⁺ cells of 14.91% (reference value 19-32.51%), CD3⁺ CD4⁺ cells of 26.01% (reference value 24.08-42.52%), CD19⁺ cells of 44.77% (reference value 13.23-26.39%), CD16⁺ CD56⁺ cells of 8.95% (reference value 7.21-20.9%), and CD4/CD8 1.74 (reference value 0.90-2.13). Epstein-Barr virus and cytomegalovirus DNA detection and antibodies (IgG and IgM) in serum were negative. Further, tuberculosis skin test and interferon-gamma release assay (IGRA) were negative. In addition, blood, urine, and stool culture were all negative. Abdomen ultrasound scan (US) and abdominal computerized tomography (CT) scan (Fig. 1) showed localized intestinal wall thickening in the right upper abdominal cavity (about 8 mm), thickening of the right upper abdominal omentum, extensive lymphadenopathy, multiple abscesses of the liver and spleen, ascites, and right hydrocele. Chest CT showed bilateral upper lobe pneumonia and pleuritis. The patient presented with fever after hospitalization and was administered with intravenous Latamoxef Sodium (70 mg/kg/day, every 12 h) and subsequently cefoperazone-sulbactam sodium (240 mg/kg/day, every 6 h) plus linezolid (30 mg/kg/day, every 8 h) due to suspected bacterial infection. The patient was also treated with IVIG (2 g/kg) but the symptoms did not improve. Abdominocentesis was performed which revealed unclear yellowish-green ascetic fluid containing 23453 cells/mm³ with neutrophilic predominance (11913 cells/mm³) and protein and glucose concentrations of 46.5 and 58.1 mg/dL respectively. Gram-staining and acid-fast staining tests were all negative. The ascites culture identified B. Contaminans. Therefore, the treatments were switched to meropenem (60 mg/kg/day, every 6 h) plus linezolid. Following this treatment, he was afebrile and showed improvement in his ascites. Due to concerns of possible underlying primary immunodeficiency, NADPH activity was tested. DHR (dihydrorhodamine)-1,2,3, can be oxidised to rhodamine-1,2,3, which emits a fluorescent signal detected by the enzyme labelling. The tests showed profound decrease in NADPH activity (139F/ug, reference value 1332-9312F/ug) and relative activity (3%, reference value 31-216%). The patient subsequently developed progressive bilateral cervical lymphadenopathy with low-grade fever. Empirical antituberculosis therapy with rifampicin (10 mg/kg/day, in a single dose) was administered which effectively...
improved the symptoms. Prednisone (1 mg/kg/day, in 2
doses) was administered orally due to persistent intes-
tinal wall thickening, elevated CRP (29-41mg/L), and
platelet count (maximum 615×10^9/L), which decreased
the intestinal wall thickening and the platelet count
to 368×10^9/L, while the CRP level to 8mg/L. After
40 days of hospitalization, the patient was discharged
on cefdinir (15mg/kg/day, in 3 doses), and was subse-
quently started on trimethoprim-sulfamethoxazole
(sulfamethoxazole 20mg/kg/day in a single dose) and
voriconazole (5mg/kg/day in a single dose) prophylaxis
along with continuation of linezolid and rifampicin.
After discharge, targeted next-generation sequenc-
ing analysis identified a nonsense variant in CYBB
gene (NM_000397.3; c.603C > A position p. Tyr201*)
(Figs. 2, 3, and 4). At a follow-up visit performed after
1 month, prednisone was stopped but the anti-infec-
tion therapies were continued. Up to now, his clinical
presentation is normal and there is no signs of the dis-
ease. Hematopoietic stem cell transplantation (HSCT)
was recommended.

Discussion
Clinically, XLR-CGD is prevalent in men and is car-
ried by women [5]. Recurrent infections are common in
patients with CGD. Moreover, CGD may present with
granulomas or inflammatory disorders. The infections
commonly affect the lungs, skin, lymph nodes, gastroin-
testinal tract and bone marrow. The common causative
pathogens are catalase-positive bacteria and fungi, such
as *Staphylococcus aureus*, *Burkholderia cepacia*, *Ser-
ratia marcescens*, *Aspergillus fumigatus*, and *Candida
albicans* [2].

In the present case, the patient did not show promi-
nent digestive tract symptoms. However, he presented
with fever, intestinal wall thickening, and ascites. Cul-
ture of the ascitic fluid showed that *B. Contaminans* was
positive. The most commonly affected organs in patients
with CGD include the gastrointestinal tract (nearly
100%), with inflammatory bowel disease (IBD) account-
ing for 33% of all cases. Inflammatory and autoimmune
complications with the X-linked inheritance pattern are
twice as high as those in patients with AR-CGD [6]. In
the present patient, invasive enteroscopy was not performed due to the rapid resolution of symptoms. Persistent intestinal wall thickening, elevated levels of CRP, IgG, platelet count, and response to glucocorticoid therapy confirmed the presence of hyperinflammation. In addition, the chest CT showed concealed pneumonia. Hydrocele in the right testes which may have been caused by unclosed sheath process resolved after the initial treatment for about ten days [7].

Burkholderia sensu stricto contains the Burkholderia cepacia complex (Bcc) and Burkholderia pseudomallei group. Both B. contaminated and B. cepacia belong to the Bcc. It is a group of gram-negative bacteria, which are common in the environment, and cause opportunistic infections. The Bcc is mostly causing pneumonia in patients with CGD and shows resistance to multiple drugs. B. contaminated is sensitive to trimethoprim-sulfamethoxazole, chloramphenicol, minocycline, ceftazidime, piperacillin/tazobactam and carbapenem [8]. It was first reported in patients with cystic fibrosis (CF) and associated with various infections, especially necrotizing pneumonia and the worsening of pulmonary function. Since then, it has been detected in patients undergoing cataract surgery and biliary tract infections, presented as endophthalmitis and sepsis respectively. It is mostly caused by contact with medical devices or contaminated aqueous solutions including nebulized medications, ultrasound gel, nasal spray, lipid emulsion, and hospital water, which may be responsible for hospital outbreaks [9–12]. BCG infections occur frequently in patients with CGD and the patient was given prophylactic anti-tuberculosis treatment (rifampicin).

Due to unusual germs and site of the patient, NADPH activity was tested, and showed a profound decrease in NADPH activity. Further, genome sequencing revealed a de novo nonsense mutation in the coding region of exon 6 of CYBB. This mutation shifts tyrosine to a premature termination codon at 201th amino acid (c. 603C > A), resulting in abnormal expression of gp91phox, and its domain is located at the N-terminal. According to recent research, about 61% of mutations in CYBB gene occur in the N-terminal domain, mostly fragment deletions and splicing errors [13, 14].

The survival of patients with CGD is closely influenced by production of residual reactive oxygen intermediates (ROIs). Compared with children with AR-CGD, those with XLR-CGD have an earlier disease onset and more severe disease leading to higher mortality. Missense mutations in CYBB can decrease levels of superoxide or gp91phox expression. In contrast, nonsense mutations inhibit the production of superoxide and protein expression, thereby decreasing the survival rate [15, 16].

Anti-infective therapy can significantly improve the quality of life and survival rate of CGD patients. Subcutaneous injection of interferon-γ decreases the risk of infection, especially in patients who acquire infections while on prophylactic antibiotics and those infected with tuberculosis [17]. Patients with CGD have excessively high levels of cytokines, such as TNF-α, IL-1, IL-8, which predispose them to hemophagocytic lymphohistiocytosis (HLH) when infected. The incidence of inflammatory complications in patients with XLR-CGD is twice as high as that in patients with AR-CGD [6, 18]. Appropriate anti-inflammatory agents, mainly corticosteroids, can significantly improve the prognosis of patients with CGD, and do not appear to increase the bacterial infection risk [3]. The recommended initial dose of prednisone is 1 mg/kg daily and to be given for an average of 2-3 weeks before being tapered over several months [19]. Biological disease modifying antirheumatic drug (bDMARDs), such as anti-TNF-a monoclonal antibodies, recombinant IL-1receptor-targeted antagonist and IL-23 antagonist have been used, but there are increased risks of infection. HSCT remains the best curative option for CGD. The major problem is the risk of infection and graft-versus-host disease (GVHD).
Lower risk patients may be best treated by HSCT. For high-risk patients and patients who have no well-matched donor, gene therapy may be considered. Although preliminary results using lentiviral vectors are fairly encouraging, gene therapy still faces many challenges [3, 20].

Conclusion

We suggest that the presence of B. Contaminans in patients with CGD should be explored. Early diagnosis is crucial to facilitate effective treatment.

Abbreviations

CGD: Chronic granulomatous disease; B. cepacia; Burkholderia contaminans; B. cepacia complex; NADPH: Nicotinamide adenine dinucleotide phosphate; BCC: Burkholderia cepacia complex; CT: Computed tomography; US: Ultrasound scan; IGR: Interferon-gamma release assay; IB: Inflammatory bowel disease; WBC: White blood cell count; MCV: Mean Corpuscular Volume; MCH: Mean Corpuscular Hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; HSCT: Hematopoietic stem cell transplantation; GVHD: Graft-versus-host disease; CF: Cystic fibrosis; ROI: Reactive oxygen intermediates; ILH: Hemophagocytic lymphohistiocytosis; DHR-1,2,3: Dyhydrorhodamine-1,2,3.

Acknowledgements

Not applicable.

Authors’ contributions

ZQJ: wrote the first draft of the manuscript and contributed to the patient management. YJ and LCW: involvement in medical diagnosis and follow up of the patient, supervision of the medical procedures and of the process of the manuscript. LXX, MJJ and WJW: involvement in diagnosis and management of the patient. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

The study was approved by Ethics Committee of Tianjin Children’s Hospital (Tianjin University Children’s Hospital).

Consent for publication

Written informed consent was obtained from the patient’s parents for publication of this case report and accompanying images.

Competing interests

The authors declare no potential competing interests with respect to the research, authorship, and/or publication of this article.

Received: 28 November 2021 Accepted: 17 March 2022

Published online: 01 April 2022

References

1. Roos D. Chronic granulomatous disease. Br Med Bull. 2016;118(1):50–63. https://doi.org/10.1093/bmbldw009 Epub 2016 Mar 16.
2. Giardino G, Cicalese MP, Delmonte O, et al. NADPH Oxidase Deficiency: A Multisystem Approach. Oxid Med Cell Longev. 2017;2017:4590127. https://doi.org/10.1155/2017/4590127.
3. Gennery A, R. Progress in treating chronic granulomatous disease. Br J Haematol. 2021;192(2):251–64. https://doi.org/10.1111/bjh.16939.
4. Rider NL, Jamerson MB, Creech CB, et al. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis. 2018;7(suppl_1):s2–5. https://doi.org/10.1093/jpids/pyy008.
5. Lewis EM, Singla M, Sergeant S, et al. X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation. Clin Immunol. 2008;129(2):372–80. https://doi.org/10.1016/j.clim.2008.07.022.
6. Magnani A, Brosselin P, Beáuté J, et al. Inflammatotary manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol. 2014;134(3):655–662.e8. https://doi.org/10.1016/j.jaci.2014.04.014.
7. Hon YS, Nakagita K, Ebrisudani Y, Aoi M, et al. Choroid Plexus Hyperplasia with Intractable Ascites and a Resulting Communicating Hydrocele following Shunt Operation for Hydrocephalus. Pediatr Neurosurg. 2018;53(6):407–12. https://doi.org/10.1159/000492333.
8. Lipuma JJ, et al. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med. 2005;11(6):528–33. https://doi.org/10.1097/01.mcp.0000181475.85187.ed.
9. Power RF, Linnane B, Martin R, et al. The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children. BMC Pulm Med. 2016;16(1):57. https://doi.org/10.1186/s12890-016-0219-2.
10. Ohji G, Ohikus K, Toguchi A, et al. Burkholderia contaminans: unusual cause of biliary sepsis. J Infect Chemother. 2013;19(5):969–71. https://doi.org/10.1016/s1001-6144(13)60156-2.
11. Lind C, Olsen K, Angelsen NK, Krefting EA, et al. Clinical course, treatment and visual outcome of an outbreak of Burkholderia contaminans endophthalmitis following cataract surgery. J Ophthalmic Inflamm Infect. 2021;11(1):12. https://doi.org/10.1186/s12348-021-00242-6.
12. Tavares M, Kozak M, Balola A, Sá-Correia I, et al. Burkholderia cepacia complex: a feared contamination risk in water-based pharmaceutical products. Clin Microbiol Rev. 2020;33(3):e00319-19. https://doi.org/10.1128/CMR.00319-19.
13. Roos D, Kuhns DB, Maddalena A, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis. 2010;45(3):246–65. https://doi.org/10.1016/j.bcmd.2010.07.012.
14. Di Matteo G, Giordani L, Finocchi A, et al. Molecular characterization of a large cohort of patients with Chronic Granulomatous Disease and identification of novel CYBB mutations: An Italian multicenter study. Mol Immunol. 2009;46(10):1935–41. https://doi.org/10.1016/j.molimm.2009.03.016.
15. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363(27):2600–10. https://doi.org/10.1056/NEJMoa1007097.
16. Stasia MJ, Li XJ, et al. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol. 2008;30(3):209–35. https://doi.org/10.1007/s00281-008-0121-8.
17. Errante PR, Frazão JB, Condino-Neto A, et al. The Use of Interferon-Gamma Therapy in Chronic Granulomatous Disease. Recent Pat Anticancer Drug Discov. 2008;2(3):225–30. https://doi.org/10.2174/15749810878624378.
18. Pareth C, Hofstra T, Church JA, et al. Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease. Pediatr Blood Cancer. 2011;56(3):460–2. https://doi.org/10.1002/pbc.22830.
19. Leiding JW, Freeman AF, Marciano BE, et al. Mariano Corticosteroid Therapy for Liver Abscess in Chronic Granulomatous Disease. Clin Infect Dis. 2012;54(5):694–700. https://doi.org/10.1093/cid/cir986.
20. Güngör T, Chiesa R, et al. Cellular Therapies in chronic granulomatous disease. Front Pediatr. 2020;8(6):327. https://doi.org/10.3389/fped.2020.00327.